| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,850 | 6,200 | 11:17 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 35,000 | 6 | |||
| 33,000 | 33 | |||
| 20,000 | 83 | |||
| 16,000 | 32 | |||
| 15,000 | 15 | |||
| 11,000 | 500 | |||
| 10,000 | 41 | |||
| 9,500 | 175 | |||
| 6,350 | 500 | |||
| 6,200 | 935 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/88q.htm [/URL] | ||||
| 935 | 5,900 | |||
| 300 | 4,900 | |||
| 700 | 4,740 | |||
| 1.061 | 0,001 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 2.996 | 0,774 | 2.320 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 09:06:32 | 6,000 | 87 |
| Tagesumsatz Xetra | +0,200 +3,45 % | 87 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Genezen to Offer Access to 4basebio Synthetic DNA Platform for Viral Vectors | 11 | Contract Pharma | ||
| Mi | 4basebio shares jump on new marketing tie-up with US-based Genezen | 9 | Alliance News | ||
| 4BASEBIO Aktie jetzt für 0€ handeln | |||||
| Mi | 4basebio and Genezen Enter into Strategic Collaboration to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing | 327 | GlobeNewswire (Europe) | Commercial collaboration combines 4basebio's synthetic DNA technology with Genezen's viral vector development and manufacturing expertise to support gene therapy programs from early development through... ► Artikel lesen | |
| Mi | 4basebio and Genezen Enter into Strategic Collaboration to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing | 240 | PR Newswire | Commercial collaboration combines 4basebio's synthetic DNA technology with Genezen's viral vector development and manufacturing expertise to support gene therapy programs from early development... ► Artikel lesen | |
| Mi | 4basebio Plc - 4basebio Enters into Strategic Collaboration and Marketing Agreement with Genezen to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing | 333 | PR Newswire | 4basebio Plc - 4basebio Enters into Strategic Collaboration and Marketing Agreement with Genezen to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing
PR... ► Artikel lesen |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 05:46 | Kursexplosion wie bei Moderna? Übernahmekandidaten Evotec, Valneva und Vidac Pharma im Check! Analysten bullisch! | ESG-Aktien.de | Moderna hat den Biotech-Markt mit dem Durchbruch bei der Bekämpfung von Hautkrebs wachgerüttelt. Partner Merck kommt in der Berichterstattung etwas zu kurz. Dabei bereitet sich der Pharmariese auf das... ► Artikel lesen | |
| 11:15 | Dividendenbekanntmachungen (01.09.2026) | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADVANCED DRAINAGE SYSTEMS INC US00790R1041 0,2 USD 0,1721 EUR AGNICO EAGLE MINES LIMITED CA0084741085 0,45 USD 0,3873 EUR AMES... ► Artikel lesen | |
| 07:03 | MindMaze Therapeutics Holding SA: MindMaze Therapeutics to Present at Upcoming Investor and Industry Conferences | EQS Group (EN) | MindMaze Therapeutics Holding SA
/ Key word(s): Conference
MindMaze Therapeutics to Present at Upcoming Investor and Industry Conferences
01.09.2026 / 07:00 CET/CEST
MindMaze... ► Artikel lesen | |
| 10:06 | Biotech Stocks At 52-Week Highs - RenovoRx +15%, Evolus, Crinetics Pharmaceuticals, Apogee Therapeutics | AFX News | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The following biotech stocks reached a 52-week high on August 31, 2026, driven by achieving new regulatory milestones or an upcoming acquisition.RenovoRx... ► Artikel lesen | |
| 07:34 | Bavarian Nordic A/S: Bavarian Nordic Launches First Tranche of New Share Buy-Back Program | GlobeNewswire (Europe) | COPENHAGEN, Denmark, September 1, 2026 - Bavarian Nordic A/S (OMX: BAVA) today launches the first tranche of the new share buy-back program announced on August 21, under which the Company intends to... ► Artikel lesen |